Recent Company News

• 11:43 AM ET Sep 09, 2025
  

  Teijin releases Integrated Report 2025 (ESG pg.88) (¥1327.0000, 0)

• 06:06 AM ET Aug 29, 2025
  

  Teijin to transfer shares in DuPont Teijin Advanced Papers (Japan) Limited and DuPont Teijin Advanced Papers (Asia) Limited to DuPont de Nemours (¥1261.0000, 0)

• 02:36 AM ET Aug 25, 2025
  

  Teijin Pharma receives manufacturing and marketing approval in Japan for YORVIPATH as treatment for hypoparathyroidism (¥1286.0000, 0)

• 03:35 AM ET Aug 07, 2025
  

  Teijin unit Teijin Aramid reports yesterday's fire at Delfzijl plant in the Netherlands (¥1294.0000, 0)

• 10:35 PM ET Aug 04, 2025
  

  Teijin reports Q1 net income attributable (¥740M) vs FactSet ¥5.40B [2 est, ¥4.30-6.50B] (¥1315.5000, +20.5)

• 04:06 AM ET Jul 22, 2025
  

  StreetAccount Sector Preview - Japan Chemicals Apr-Jun Earnings

• 02:42 AM ET Jun 24, 2025
  

  Teijin receives additional indication approval for Xeomin in Japan for treatment of chronic sialorrhea (¥1165.5000, 0)

• 10:11 PM ET Jun 02, 2025
  

  MHLW grants orphan drug designation to Teijin's navepegritide (TransCon CNP) for the treatment of chondrodysplasia (¥1136.5000, -5.5)

• 10:41 PM ET May 11, 2025
  

  Teijin reports Q4 net income attributable (¥22.60B) vs FactSet (¥25.60B) [1 est] (¥1220.0000, +15.5)

• 10:30 PM ET Apr 24, 2025
  

  StreetAccount Sector Preview - Japan Chemicals Jan-Mar Earnings